The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

Abstract Background The PAM50-based (Prosigna) risk of recurrence (ROR) score and intrinsic subtypes are prognostic for women with high-risk breast cancer. We investigate the predictive ability of Prosigna regarding the effectiveness of cyclophosphamide-based adjuvant chemotherapy in premenopausal p...

Full description

Bibliographic Details
Main Authors: Maj-Britt Jensen, Anne-Vibeke Lænkholm, Torsten O. Nielsen, Jens Ole Eriksen, Pernille Wehn, Tressa Hood, Namratha Ram, Wesley Buckingham, Sean Ferree, Bent Ejlertsen
Format: Article
Language:English
Published: BMC 2018-07-01
Series:Breast Cancer Research
Subjects:
Breast neoplasms
Adjuvant chemotherapy
Cyclophosphamide
CMF
PAM50
Online Access:http://link.springer.com/article/10.1186/s13058-018-1012-0

Internet

http://link.springer.com/article/10.1186/s13058-018-1012-0

Similar Items